Concepedia

Author

Gladys Rodriguez

The University of Texas Health Science Center at San AntonioORCID

Also Known As

G I Rodriguez, G Rodriguez, G. I. Rodriguez, G. Rodriguez, G. Rodríguez, G.I. Rodriguez, Gladys I Rodriguez, Gladys I Rodriguez,, Gladys I. Rodriguez, Gladys Isabel Rodriguez

84

Publications

4.8K

Citations

28

H-Index

71

Concepts

All Affiliations

The University of Texas Health Science Center at San AntonioTexas OncologyBrooke Army Medical CenterTennessee OncologySarah Cannon
GR

About

Gladys Rodriguez is an author at The University of Texas Health Science Center at San Antonio specializing in medicine, oncology, and cancer therapeutics.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

17

24

3.1K

2

Health Sciences

7

7

2.5K

3

Education

1

1

13

4

Natural Sciences

1

1

24

5

Nursing

1

1

84

Gladys Rodriguez

×

42

Publications

4.6K

Citations

27

H-Index

YearCitations

Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study

Sandra M. Swain, David Miles, Sung‐Bae Kim,

The Lancet Oncology

2020

854

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

Miguel Martín, Frankie A. Holmes, Bent Ejlertsen,

The Lancet Oncology

2017

578

Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Arlene Chan, Suzette Delaloge, Frankie A. Holmes,

The Lancet Oncology

2016

551

A Phase II Study of Trastuzumab Emtansine in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer Who Were Previously Treated With Trastuzumab, Lapatinib, an Anthracycline, a Taxane, and Capecitabine

Ian E. Krop, Patricia LoRusso, Kathy D. Miller,

Journal of Clinical Oncology

2012

361

Overall Survival Improvement in Patients with Lung Cancer and Bone Metastases Treated with Denosumab Versus Zoledronic Acid: Subgroup Analysis from a Randomized Phase 3 Study

Giorgio V. Scagliotti, Vera Hirsh, Salvatore Siena,

Journal of Thoracic Oncology

2012

339

Projected Supply of and Demand for Oncologists and Radiation Oncologists Through 2025: An Aging, Better-Insured Population Will Result in Shortage

Wenya Yang, James Williams, Paul F. Hogan,

Journal of Oncology Practice

2014

245

A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation

David Rinaldi, John G. Kuhn, Howard A. Burris,

Cancer Chemotherapy and Pharmacology

1999

174

Initial phase I evaluation of the novel thymidylate synthase inhibitor, LY231514, using the modified continual reassessment method for dose escalation.

David Rinaldi, Howard A. Burris, F. Andrew Dorr,

Journal of Clinical Oncology

1995

152

Phase I clinical trial of taxotere administered as either a 2-hour or 6-hour intravenous infusion.

Howard A. Burris, Rebecca Irvin, John G. Kuhn,

Journal of Clinical Oncology

1993

135

A phase I clinical and pharmacokinetic study of the topoisomerase I inhibitor topotecan (SK&F 104864) given as an intravenous bolus every 21 days

James G. Wall, Howard A. Burris, Daniel D. Von Hoff,

Anti-Cancer Drugs

1992

113

Page 1